In a guest post on Inside Prevention, a blog provided by the Breast Cancer Fund, Maricel Maffini, Senior Scientists at the Natural Resources Defense Council (NRDC), argues that the U.S. Food and Drug Administration’s (FDA) recent publication of the CLARITY pilot study jumps the gun on bisphenol A (BPA) thereby undermining ongoing safety research (previously reported on by the FPF). The NRDC scientist contends that concluding on BPA’s safety appears premature when major BPA research under the CLARITY project is still ongoing for another 3 to 4 years. The experiments on BPA carried out by the CLARITY consortium are intended to address a wide variety of diseases and low dose exposures over the entire lifetime. In the article, Maffini points to European decisions to revise BPA’s current cancer classification and lower the tolerable daily intake (TDI) of BPA. She recommends the FDA to await the full data from the CLARITY and to rigorously evaluate all available information, rather than rushing to a conclusion on BPA’s safety.
Maricel Maffini (May 1, 2014). “FDA jumps the gun on bisphenol A and undermines ongoing safety research.” Breast Cancer Fund.
FPF article “Opinion: New FDA study on BPA is flawed”